MannKind Corporation (MNKD)
After hours:
| Previous close | 4.1000 |
| Open | 4.1100 |
| Bid | 4.0500 x 400 |
| Ask | 4.1000 x 700 |
| Day's range | 4.0500 - 4.2200 |
| 52-week range | 3.1700 - 5.7500 |
| Volume | |
| Avg. volume | 2,951,658 |
| Market cap | 1.105B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.08 |
GlobeNewswireMannKind Repays Certain Debt Obligations
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 millionTotal debt reduced since December 31, 2023 is approximately $41.8 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled thera
Simply Wall St.MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their...
ZacksIovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
